Nicole Hildebrand
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nicole Hildebrand has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
- Daniel Strech
QUEST Center for Responsible Research, Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany
6 shared publications - Samruddhi Yerunkar
QUEST Center for Responsible Research, Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany
5 shared publications - Delwen Louise Franzen
QUEST Center for Responsible Research, Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany
4 shared publications - Emmanuel A. Zavalis
Meta-Research Innovation Center at Stanford (METRICS), Stanford University
4 shared publications - Maia Salholz-Hillel
QUEST Center for Responsible Research, Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Berlin, Germany
3 shared publications - Susanne Wieschowski
QUEST Center for Responsible Research, Berlin Institute of Health at Charité – Universitätsmedizin Berlin
3 shared publications
Latest Publications
- Open Access
Towards monitoring of global health research: an exploratory analysis of transparency and stakeholder engagement
Objectives: Monitoring systems exist for clinical research transparency in high-income countries, but systematic assessment of these practices in global health (GH) research (GHR) is limited. We evaluated methods for monitoring GHR transparency and engagement. Design: Cross-sectional study. Data sources: Three sources were used: (a) ClinicalTrials.gov , (b) publications from 20 journals with ‘international’ or ‘global’ in the title and (c) outputs from selected GH funder websites. Eligibility criteria: From ClinicalTrials.gov , we selected 200 interventional trials on maternal health and tuberculosis (2008–2019), ensuring two-thirds were from low- and middle-income countries (LMIC). From journals, we included 200 trial publications (2011–2023). From funder websites, we included outputs with sufficient metadata to track trial registration and reporting. Data extraction and synthesis: Trials were extracted independently by two reviewers for result publications; journal articles were screened to confirm whether they reported trial results. Across all sources, we assessed registration timing, result reporting, open access and stakeholder engagement. Results: For 200 trials, 37% were prospectively registered, 65% published results in journals and 15% reported summary results in ClinicalTrials.gov . Only 34% reported results in any format within 24 months of completion. Of 200 publications, 72% were freely accessible, and 23% of the 100-article subsample included stakeholder engagement statements. The funder website sample yielded insufficient metadata for analysis. Conclusions: Monitoring GHR is feasible using registries and journals, though funder websites provide limited tracking. While open-access rates are encouraging, timely reporting and engagement documentation remain weak. These results highlight opportunities for developing GHR-specific monitoring approaches through collaborative efforts among global stakeholders.
Open AccessTowards monitoring of global health research: an exploratory analysis of transparency and stakeholder engagement
Objectives: Monitoring systems exist for clinical research transparency in high-income countries, but systematic assessment of these practices in global health (GH) research (GHR) is limited. We evaluated methods for monitoring GHR transparency and engagement. Design: Cross-sectional study. Data sources: Three sources were used: (a) ClinicalTrials.gov , (b) publications from 20 journals with ‘international’ or ‘global’ in the title and (c) outputs from selected GH funder websites. Eligibility criteria: From ClinicalTrials.gov , we selected 200 interventional trials on maternal health and tuberculosis (2008–2019), ensuring two-thirds were from low- and middle-income countries (LMIC). From journals, we included 200 trial publications (2011–2023). From funder websites, we included outputs with sufficient metadata to track trial registration and reporting. Data extraction and synthesis: Trials were extracted independently by two reviewers for result publications; journal articles were screened to confirm whether they reported trial results. Across all sources, we assessed registration timing, result reporting, open access and stakeholder engagement. Results: For 200 trials, 37% were prospectively registered, 65% published results in journals and 15% reported summary results in ClinicalTrials.gov . Only 34% reported results in any format within 24 months of completion. Of 200 publications, 72% were freely accessible, and 23% of the 100-article subsample included stakeholder engagement statements. The funder website sample yielded insufficient metadata for analysis. Conclusions: Monitoring GHR is feasible using registries and journals, though funder websites provide limited tracking. While open-access rates are encouraging, timely reporting and engagement documentation remain weak. These results highlight opportunities for developing GHR-specific monitoring approaches through collaborative efforts among global stakeholders.
- Open Access
- 1 December 2025
- Published by Springer Nature in Trials
- Vol. 27 (1)
Registration and reporting of clinical trials affiliated with California universities and with primary completion date from 2014 to 2017
Background: Public information on US clinical trials is shared through the ClinicalTrials.gov registry. This study’s goal was to determine prospective registration, results reporting, trial registration number reporting, and publication accessibility status for trials with primary completion dates from 2014 to 2017 affiliated with seven California universities. Methods: We identified trials with investigators, sponsors, or responsible parties affiliated with seven California universities and searched for their results publications manually. We then used semi-automatic methods to determine prospective registration, summary results reporting in a registry, publication status, and reporting of registration numbers in the abstract and the full text of manuscripts. Results: We identified 1091 unique trials. Most trials were single-center ( n = 752, 69%) and had a median of 50 participants (IQR 21 to 150). Overall, 64% of trials ( n = 698) were prospectively registered, 46% ( n = 500) had summary results reported in the registry, 69% ( n = 750) had results published as articles, and an additional 3% ( n = 36) as abstracts or posters. Results reporting (summary, articles, abstracts or posters) occurred for 58% of trials ( n = 637) within 2 years, and for 81% ( n = 888) within 5 years of the study’s primary completion date. Of journal publications, 77% ( n = 579) were open access publications, 37% ( n = 276) had trial registration numbers listed in their abstract, and 45% ( n = 336) in the manuscript. Only 92 (8%) of these trials were legally required to report results, and only 2 (2%) of those were overdue and under the primary responsibility of a California university to report. Conclusions: Almost one fifth of clinical trials with primary completion dates from 2014 to 2017 with investigators, sponsors or responsible parties affiliated with seven California biomedical research universities lacked any results reporting 5 years after their primary completion, and only 58% reported results within 2 years. Even though a large majority of these trials were completed before US legal mandates for reporting, there was an ethical requirement that the burden to research participants should be commensurate with the scientific value of the research. Research has no public scientific value if its results are not reported.
- 1 December 2025
- Published by Springer Nature in Trials
- Vol. 27 (1)
Open AccessRegistration and reporting of clinical trials affiliated with California universities and with primary completion date from 2014 to 2017
Background: Public information on US clinical trials is shared through the ClinicalTrials.gov registry. This study’s goal was to determine prospective registration, results reporting, trial registration number reporting, and publication accessibility status for trials with primary completion dates from 2014 to 2017 affiliated with seven California universities. Methods: We identified trials with investigators, sponsors, or responsible parties affiliated with seven California universities and searched for their results publications manually. We then used semi-automatic methods to determine prospective registration, summary results reporting in a registry, publication status, and reporting of registration numbers in the abstract and the full text of manuscripts. Results: We identified 1091 unique trials. Most trials were single-center ( n = 752, 69%) and had a median of 50 participants (IQR 21 to 150). Overall, 64% of trials ( n = 698) were prospectively registered, 46% ( n = 500) had summary results reported in the registry, 69% ( n = 750) had results published as articles, and an additional 3% ( n = 36) as abstracts or posters. Results reporting (summary, articles, abstracts or posters) occurred for 58% of trials ( n = 637) within 2 years, and for 81% ( n = 888) within 5 years of the study’s primary completion date. Of journal publications, 77% ( n = 579) were open access publications, 37% ( n = 276) had trial registration numbers listed in their abstract, and 45% ( n = 336) in the manuscript. Only 92 (8%) of these trials were legally required to report results, and only 2 (2%) of those were overdue and under the primary responsibility of a California university to report. Conclusions: Almost one fifth of clinical trials with primary completion dates from 2014 to 2017 with investigators, sponsors or responsible parties affiliated with seven California biomedical research universities lacked any results reporting 5 years after their primary completion, and only 58% reported results within 2 years. Even though a large majority of these trials were completed before US legal mandates for reporting, there was an ethical requirement that the burden to research participants should be commensurate with the scientific value of the research. Research has no public scientific value if its results are not reported.
- Open Access
Registration and Reporting of Clinical Trials Affiliated with California Universities and with Primary Completion Date from 2014 to 2017
Background Public information on US clinical trials is shared through the ClinicalTrials.gov registry. This study’s goal was to determine prospective registration, results reporting, trial registration number reporting, and publication accessibility status for trials with primary completion dates from 2014 to 2017 affiliated with seven California universities. Methods We identified trials with investigators, sponsors, or responsible parties affiliated with seven California universities and searched for their results publications manually. We then used semi-automatic methods to determine prospective registration, summary results reporting in a registry, publication status, and reporting of registration numbers in the abstract and the full text of manuscripts. Results We identified 1,091 unique trials. Most trials were single-center (n=752, 69%) and had a median of 50 participants (IQR 21 to 150). Overall, 64% of trials (n=698) were prospectively registered, 46% (n=500) had summary results reported in the registry, 69% (n=750) had results published as articles, and an additional 3% (n=36) as abstracts or posters. Results reporting (summary, articles, abstracts or posters) occurred for 58% of trials (n=637) within 2 years, and for 81% (n=888) within 5 years of study primary completion date. Of journal publications, 77% (n=579) were open access publications, 37% (n=276) had trial registration numbers listed in their abstract, and 45% (n=336) in the manuscript. Only 92 (8%) of these trials were legally required to report results, and only 2 (2%) of those were overdue and under primary responsibility of a California university to report. Conclusions Almost one fifth of clinical trials with primary completion dates from 2014 to 2017 with investigators, sponsors or responsible parties affiliated with seven California biomedical research universities lacked any results reporting 5 years after their primary completion, and only 58% reported results within 2 years. Even though a large majority of these trials were completed before US legal mandates for reporting, there was an ethical requirement that the burden to research participants should be commensurate with the scientific value of the research. Research has no public scientific value if its results are not reported.
Open AccessRegistration and Reporting of Clinical Trials Affiliated with California Universities and with Primary Completion Date from 2014 to 2017
Background Public information on US clinical trials is shared through the ClinicalTrials.gov registry. This study’s goal was to determine prospective registration, results reporting, trial registration number reporting, and publication accessibility status for trials with primary completion dates from 2014 to 2017 affiliated with seven California universities. Methods We identified trials with investigators, sponsors, or responsible parties affiliated with seven California universities and searched for their results publications manually. We then used semi-automatic methods to determine prospective registration, summary results reporting in a registry, publication status, and reporting of registration numbers in the abstract and the full text of manuscripts. Results We identified 1,091 unique trials. Most trials were single-center (n=752, 69%) and had a median of 50 participants (IQR 21 to 150). Overall, 64% of trials (n=698) were prospectively registered, 46% (n=500) had summary results reported in the registry, 69% (n=750) had results published as articles, and an additional 3% (n=36) as abstracts or posters. Results reporting (summary, articles, abstracts or posters) occurred for 58% of trials (n=637) within 2 years, and for 81% (n=888) within 5 years of study primary completion date. Of journal publications, 77% (n=579) were open access publications, 37% (n=276) had trial registration numbers listed in their abstract, and 45% (n=336) in the manuscript. Only 92 (8%) of these trials were legally required to report results, and only 2 (2%) of those were overdue and under primary responsibility of a California university to report. Conclusions Almost one fifth of clinical trials with primary completion dates from 2014 to 2017 with investigators, sponsors or responsible parties affiliated with seven California biomedical research universities lacked any results reporting 5 years after their primary completion, and only 58% reported results within 2 years. Even though a large majority of these trials were completed before US legal mandates for reporting, there was an ethical requirement that the burden to research participants should be commensurate with the scientific value of the research. Research has no public scientific value if its results are not reported.
- Open Access
- 1 February 2025
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 181, 111710
Results reporting for clinical trials led by medical universities and university hospitals in the nordic countries was often missing or delayed
- 1 February 2025
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 181, 111710
Open AccessResults reporting for clinical trials led by medical universities and university hospitals in the nordic countries was often missing or delayed
- Open Access
Towards Monitoring of Global Health Research: An Exploratory Analysis of Transparency and Stakeholder Engagement
Introduction: Global health research (GHR) requires transparent practices and stakeholder engagement to maximize impact. While monitoring systems exist for clinical research transparency in high-income countries, there is limited systematic assessment of these practices in global health research. This study evaluated methods for monitoring GHR transparency and engagement practices using established indicators. Methods: We analyzed three samples: (1) 200 interventional trials from ClinicalTrials.gov (2008-2019) focused on tuberculosis and maternal health, with two-thirds from low-and-middle-income countries; (2) 200 trial publications from global health journals (2011-2023); and (3) research outputs from global health funder websites. We assessed registration timing, result reporting, open access status, and stakeholder engagement using standardized indicators. Results: Among registry trials, 37% were prospectively registered, 65% published results in journals, and 15% reported summary results in ClinicalTrials.gov . Only 34% reported results in any format within 24 months of completion. For journal publications, 72% were freely accessible, and among a subsample of 100 articles, 23% included stakeholder engagement statements. The funder website sample yielded insufficient metadata for systematic analysis. Conclusion: Our findings demonstrate that monitoring GHR transparency and engagement is feasible using trial registries and journal publications, though funder websites currently lack adequate tracking data. While open access rates are encouraging, timely result reporting and stakeholder engagement documentation need improvement. These results highlight opportunities for developing GHR-specific monitoring approaches through collaborative efforts among global stakeholders. Funding: Berlin University Alliance What is already known on this topic: Previous studies have highlighted gaps in transparency and patient engagement in clinical trials. To address these, various tools, such as national and university dashboards, have been developed to monitor practices. In global health research (GHR), this monitoring has been primarily led by intergovernmental agencies; however, academic research can complement these efforts by enhancing rigor and driving actionable change. This study proposes a methodological approach to identify global health studies for analysis with established research indicators and aims to suggest complementary strategies for analyzing GHR. What this study adds: This study introduces a methodology suitable for assessing GHR studies with transparency and engagement indicators. We sourced data from trial registry, global health journals, and funder websites, providing accompanying code and data to facilitate reproducibility for other researchers in the field. Unlike prior analyses in global health context that often emphasize LMICs, our approach incorporates both LMIC and HIC studies, recognizing the collaborative foundation of GHR and encouraging shared contextualized findings. Our findings offer empirical data while underscoring the need for expanded collaboration to refine indicators and methodologies, enhancing the contextual relevance of GHR monitoring. How this study might affect research, practice or policy: Collaborative efforts among researchers, funders, and communities are essential to develop new methodologies and indicators that focus on actionable change highlighted by continuous monitoring. While often led by large organizations, GHR monitoring can be enriched by academic research, making it more contextualized and accessible to global health researchers. By proposing initial methodologies, we provide a foundation that can be refined along with indicators that can be contextualized, both of which are essential for driving effective global health research.
Open AccessTowards Monitoring of Global Health Research: An Exploratory Analysis of Transparency and Stakeholder Engagement
Introduction: Global health research (GHR) requires transparent practices and stakeholder engagement to maximize impact. While monitoring systems exist for clinical research transparency in high-income countries, there is limited systematic assessment of these practices in global health research. This study evaluated methods for monitoring GHR transparency and engagement practices using established indicators. Methods: We analyzed three samples: (1) 200 interventional trials from ClinicalTrials.gov (2008-2019) focused on tuberculosis and maternal health, with two-thirds from low-and-middle-income countries; (2) 200 trial publications from global health journals (2011-2023); and (3) research outputs from global health funder websites. We assessed registration timing, result reporting, open access status, and stakeholder engagement using standardized indicators. Results: Among registry trials, 37% were prospectively registered, 65% published results in journals, and 15% reported summary results in ClinicalTrials.gov . Only 34% reported results in any format within 24 months of completion. For journal publications, 72% were freely accessible, and among a subsample of 100 articles, 23% included stakeholder engagement statements. The funder website sample yielded insufficient metadata for systematic analysis. Conclusion: Our findings demonstrate that monitoring GHR transparency and engagement is feasible using trial registries and journal publications, though funder websites currently lack adequate tracking data. While open access rates are encouraging, timely result reporting and stakeholder engagement documentation need improvement. These results highlight opportunities for developing GHR-specific monitoring approaches through collaborative efforts among global stakeholders. Funding: Berlin University Alliance What is already known on this topic: Previous studies have highlighted gaps in transparency and patient engagement in clinical trials. To address these, various tools, such as national and university dashboards, have been developed to monitor practices. In global health research (GHR), this monitoring has been primarily led by intergovernmental agencies; however, academic research can complement these efforts by enhancing rigor and driving actionable change. This study proposes a methodological approach to identify global health studies for analysis with established research indicators and aims to suggest complementary strategies for analyzing GHR. What this study adds: This study introduces a methodology suitable for assessing GHR studies with transparency and engagement indicators. We sourced data from trial registry, global health journals, and funder websites, providing accompanying code and data to facilitate reproducibility for other researchers in the field. Unlike prior analyses in global health context that often emphasize LMICs, our approach incorporates both LMIC and HIC studies, recognizing the collaborative foundation of GHR and encouraging shared contextualized findings. Our findings offer empirical data while underscoring the need for expanded collaboration to refine indicators and methodologies, enhancing the contextual relevance of GHR monitoring. How this study might affect research, practice or policy: Collaborative efforts among researchers, funders, and communities are essential to develop new methodologies and indicators that focus on actionable change highlighted by continuous monitoring. While often led by large organizations, GHR monitoring can be enriched by academic research, making it more contextualized and accessible to global health researchers. By proposing initial methodologies, we provide a foundation that can be refined along with indicators that can be contextualized, both of which are essential for driving effective global health research.
- Open Access
Results reporting for clinical trials led by medical universities and university hospitals in the Nordic countries was often missing or delayed
Objective To systematically evaluate timely reporting of clinical trial results at medical universities and university hospitals in the Nordic countries. Study Design and Setting In this cross-sectional study, we included trials (regardless of intervention) registered in the EU Clinical Trials Registry and/or ClinicalTrials.gov, completed 2016-2019, and led by a university with medical faculty or university hospital in Denmark, Finland, Iceland, Norway, or Sweden. We identified summary results posted at the trial registries, and conducted systematic manual searches for results publications (e.g., journal articles, preprints). We present proportions with 95% confidence intervals (CI), and medians with interquartile range (IQR). Protocol: https://osf.io/wua3r Results Among 2,113 included clinical trials, 1,638 (77.5%, 95%CI 75.9-79.2%) reported any results during our follow-up; 1,092 (51.7%, 95%CI 49.5-53.8%) reported any results within 2 years of the global completion date; and 42 (2%, 95%CI 1.5-2.7%) posted summary results in the registry within 1 year. Median time from global completion date to results reporting was 698 days (IQR 1,123). 856/1,681 (50.9%) of ClinicalTrials.gov-registrations were prospective. Denmark contributed approximately half of all trials. Reporting performance varied widely between institutions. Conclusion Missing and delayed results reporting of academically-led clinical trials is a pervasive problem in the Nordic countries. We relied on trial registry information, which can be incomplete. Institutions, funders, and policy makers need to support trial teams, ensure regulation adherence, and secure trial reporting before results are permanently lost. What is new? - Many Nordic registered clinical trials were reported late or not at all. - Almost one in four trials remained unreported at the end of our search period. - About half of registered trials had reported results two years after completion. - Only 2% of trials posted summary results in the registry one year after completion. - Concerted action is needed to improve reporting of Nordic clinical trials.
Open AccessResults reporting for clinical trials led by medical universities and university hospitals in the Nordic countries was often missing or delayed
Objective To systematically evaluate timely reporting of clinical trial results at medical universities and university hospitals in the Nordic countries. Study Design and Setting In this cross-sectional study, we included trials (regardless of intervention) registered in the EU Clinical Trials Registry and/or ClinicalTrials.gov, completed 2016-2019, and led by a university with medical faculty or university hospital in Denmark, Finland, Iceland, Norway, or Sweden. We identified summary results posted at the trial registries, and conducted systematic manual searches for results publications (e.g., journal articles, preprints). We present proportions with 95% confidence intervals (CI), and medians with interquartile range (IQR). Protocol: https://osf.io/wua3r Results Among 2,113 included clinical trials, 1,638 (77.5%, 95%CI 75.9-79.2%) reported any results during our follow-up; 1,092 (51.7%, 95%CI 49.5-53.8%) reported any results within 2 years of the global completion date; and 42 (2%, 95%CI 1.5-2.7%) posted summary results in the registry within 1 year. Median time from global completion date to results reporting was 698 days (IQR 1,123). 856/1,681 (50.9%) of ClinicalTrials.gov-registrations were prospective. Denmark contributed approximately half of all trials. Reporting performance varied widely between institutions. Conclusion Missing and delayed results reporting of academically-led clinical trials is a pervasive problem in the Nordic countries. We relied on trial registry information, which can be incomplete. Institutions, funders, and policy makers need to support trial teams, ensure regulation adherence, and secure trial reporting before results are permanently lost. What is new? - Many Nordic registered clinical trials were reported late or not at all. - Almost one in four trials remained unreported at the end of our search period. - About half of registered trials had reported results two years after completion. - Only 2% of trials posted summary results in the registry one year after completion. - Concerted action is needed to improve reporting of Nordic clinical trials.